发布求助
文献互助 智能选刊 最新文献

Cancer journal最新文献

筛选
英文 中文
Hepatocellular Carcinoma-Southeast Asia Updates. 东南亚肝细胞癌最新消息。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-09-01 DOI: 10.1097/PPO.0000000000000684
Satender Pal Singh, Vinod Arora, Tushar Madke, Shiv Kumar Sarin
{"title":"Hepatocellular Carcinoma-Southeast Asia Updates.","authors":"Satender Pal Singh,&nbsp;Vinod Arora,&nbsp;Tushar Madke,&nbsp;Shiv Kumar Sarin","doi":"10.1097/PPO.0000000000000684","DOIUrl":"10.1097/PPO.0000000000000684","url":null,"abstract":"<p><strong>Abstract: </strong>Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide. Classically, HCC develops in genetically susceptible individuals who are exposed to risk factors, especially in the presence of liver cirrhosis. Significant temporal and geographic variations exist for HCC and its etiologies. Over time, the burden of HCC has shifted from the low-moderate to the high sociodemographic index regions, reflecting the transition from viral to nonviral causes. Geographically, the hepatitis viruses predominate as the causes of HCC in Asia and Africa. Although there are genetic conditions that confer increased risk for HCC, these diagnoses are rarely recognized outside North America and Europe. In this review, we evaluate the epidemiologic trends and risk factors of HCC and discuss the prevention with surveillance and short management.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 5","pages":"259-265"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41108544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma? 放射治疗在肝内胆管癌分子时代扮演什么角色？
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-09-01 DOI: 10.1097/PPO.0000000000000685
Eugene J Koay, Milind Javle, Madeline Belknap, Shrey Derasari, Millicent Roach, Ethan B Ludmir
{"title":"What Role Does Radiotherapy Play in the Molecular Era for Intrahepatic Cholangiocarcinoma?","authors":"Eugene J Koay,&nbsp;Milind Javle,&nbsp;Madeline Belknap,&nbsp;Shrey Derasari,&nbsp;Millicent Roach,&nbsp;Ethan B Ludmir","doi":"10.1097/PPO.0000000000000685","DOIUrl":"10.1097/PPO.0000000000000685","url":null,"abstract":"ABSTRACT\u0000Intrahepatic cholangiocarcinoma is a rare disease, yet with rising incidence globally. Most patients are not eligible for potentially curative surgical resection, and many patients with unresectable disease die within 12 months of diagnosis, primarily due to liver failure from the primary tumor. Recent prospective and retrospective studies indicate that local control of the primary tumor can be achieved with hypofractionated radiotherapy in patients with unresectable disease, translating into prolonged survival of these patients. During the time that these encouraging reports for radiotherapy have been published, numerous concurrent studies have also shown that intrahepatic cholangiocarcinoma is a molecularly diverse disease with multiple targetable genetic alterations and a complex tumor microenvironment. These biological insights have translated into new drug approvals for subsets of patients. We review the current knowledge about the biology and targeted treatment of intrahepatic cholangiocarcinoma and describe these developments in the context of modern radiotherapy.","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 5","pages":"272-278"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41119814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of Response-Based Radiotherapy for Hepatocellular Cancer. 基于响应的癌症放射治疗进展。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-09-01 DOI: 10.1097/PPO.0000000000000679
Ameer L Elaimy, Yue Cao, Theodore S Lawrence
{"title":"Evolution of Response-Based Radiotherapy for Hepatocellular Cancer.","authors":"Ameer L Elaimy, Yue Cao, Theodore S Lawrence","doi":"10.1097/PPO.0000000000000679","DOIUrl":"10.1097/PPO.0000000000000679","url":null,"abstract":"<p><strong>Abstract: </strong>Stereotactic body radiation therapy has emerged as a safe and effective treatment modality for properly selected hepatocellular cancer (HCC) patients with normal liver function. However, many HCC patients have reduced baseline liver function due to underlying cirrhosis or prior liver-directed therapies. Therefore, because of the increased risk of hepatotoxicity, the use of stereotactic body radiation therapy for patients with reduced liver function has been approached with caution. Individualized, response-based radiotherapy incorporates models, imaging tools, and biomarkers that determine the dose-response relationship of the liver before, during, and after treatment and has been useful in reducing the likelihood of liver damage without sacrificing tumor control. This review discusses the evolution of response-based radiotherapy for HCC and highlights areas for further investigation.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 5","pages":"266-271"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocellular Carcinoma Genetic Classification. 肝细胞癌基因分类。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-09-01 DOI: 10.1097/PPO.0000000000000682
Zurabi Lominadze, Mohammed Rifat Shaik, Dabin Choi, Duha Zaffar, Lopa Mishra, Kirti Shetty
{"title":"Hepatocellular Carcinoma Genetic Classification.","authors":"Zurabi Lominadze, Mohammed Rifat Shaik, Dabin Choi, Duha Zaffar, Lopa Mishra, Kirti Shetty","doi":"10.1097/PPO.0000000000000682","DOIUrl":"10.1097/PPO.0000000000000682","url":null,"abstract":"<p><strong>Abstract: </strong>Hepatocellular carcinoma (HCC) represents a significant global burden, with management complicated by its heterogeneity, varying presentation, and relative resistance to therapy. Recent advances in the understanding of the genetic, molecular, and immunological underpinnings of HCC have allowed a detailed classification of these tumors, with resultant implications for diagnosis, prognostication, and selection of appropriate treatments. Through the correlation of genomic features with histopathology and clinical outcomes, we are moving toward a comprehensive and unifying framework to guide our diagnostic and therapeutic approach to HCC.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 5","pages":"249-258"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41101495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Prognostic Role of Liver Metastases on Patient Outcomes: Systematic Review and Meta-analysis. 评估肝转移对患者预后的影响：系统综述和荟萃分析。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-09-01 DOI: 10.1097/PPO.0000000000000683
Jessica J Waninger, Vincent T Ma, Zoey Chopra, Ashley N Pearson, Michael D Green
{"title":"Evaluation of the Prognostic Role of Liver Metastases on Patient Outcomes: Systematic Review and Meta-analysis.","authors":"Jessica J Waninger, Vincent T Ma, Zoey Chopra, Ashley N Pearson, Michael D Green","doi":"10.1097/PPO.0000000000000683","DOIUrl":"10.1097/PPO.0000000000000683","url":null,"abstract":"<p><strong>Abstract: </strong>The liver is a common site of metastasis for many primary malignancies, but the quantitative impact on survival is unknown. We performed a systematic review and meta-analysis of 83 studies (604,853 patients) assessing the overall hazard associated with liver metastases by primary tumor type and treatment regimen. The pooled overall survival hazard ratio (HR) for all included studies was 1.77 (95% confidence interval [CI], 1.62-1.93). Patients with breast cancer primaries fared the worst (HR, 2.37; 95% CI, 1.64-3.44), as did patients treated with immunotherapies (HR, 1.86; 95% CI, 1.42-2.42). Liver metastases negatively impact survival, necessitating new approaches to disease management.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 5","pages":"279-284"},"PeriodicalIF":2.2,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41107507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival of the Fittest: How Adaptive Medicine Can Enhance Cancer Treatment. 适者生存：适应性医学如何加强癌症治疗。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000673
J Chad Brenner
{"title":"Survival of the Fittest: How Adaptive Medicine Can Enhance Cancer Treatment.","authors":"J Chad Brenner","doi":"10.1097/PPO.0000000000000673","DOIUrl":"10.1097/PPO.0000000000000673","url":null,"abstract":"","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 4","pages":"213-214"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9845068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer. 人乳头瘤病毒循环肿瘤DNA在口咽癌症中的作用。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000667
Samuel N Regan, Michelle L Mierzwa
{"title":"The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer.","authors":"Samuel N Regan,&nbsp;Michelle L Mierzwa","doi":"10.1097/PPO.0000000000000667","DOIUrl":"10.1097/PPO.0000000000000667","url":null,"abstract":"<p><strong>Abstract: </strong>Human papillomavirus infection is currently implicated in the majority of oropharyngeal squamous cell carcinoma cases diagnosed in the United States. Circulating tumor DNA (ctDNA) has emerged as a potential biomarker for human papillomavirus-related oropharyngeal squamous cell carcinoma and has the opportunity to improve the diagnosis, treatment, and surveillance of patients with this disease. Changes in ctDNA levels during and after primary therapy may be related to disease response, which can possibly have implications for treatment intensification or de-escalation strategies. Further, ctDNA seems to be sensitive and specific for disease recurrence and may improve upon current methods for assessing both treatment response and failure. In this review, we examine the relevant literature on the use of ctDNA for oropharyngeal cancer treatment and surveillance and discuss current limitations and future directions for this promising biomarker.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 4","pages":"226-229"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9835654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Apparent Diffusion Coefficient Established as an Imaging Biomarker for Stereotactic Body Radiation Therapy Assessment in Hepatocellular Carcinoma? 表观扩散系数是否被确定为肝细胞癌立体定向放射治疗评估的成像生物标志物？
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000668
Yue Cao, Kyle C Cuneo, Joseph Evans, Randall K Ten Haken, Daniel T Chang, Theodore S Lawrence
{"title":"Is Apparent Diffusion Coefficient Established as an Imaging Biomarker for Stereotactic Body Radiation Therapy Assessment in Hepatocellular Carcinoma?","authors":"Yue Cao, Kyle C Cuneo, Joseph Evans, Randall K Ten Haken, Daniel T Chang, Theodore S Lawrence","doi":"10.1097/PPO.0000000000000668","DOIUrl":"10.1097/PPO.0000000000000668","url":null,"abstract":"<p><strong>Abstract: </strong>In this article, as part of this special issue on biomarkers of early response, we review currently available reports regarding magnetic resonance imaging apparent diffusion coefficient (ADC) changes in hepatocellular carcinoma (HCC) in response to stereotactic body radiation therapy. We compare diffusion image acquisition, ADC analysis, methods for HCC response assessment, and statistical methods for prediction of local tumor progression by ADC metrics. We discuss the pros and cons of these studies. Following detailed analyses of existing investigations, we cannot conclude that ADC is established as an imaging biomarker for stereotactic body radiation therapy assessment in HCC.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 4","pages":"238-242"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9881984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer. 癌症前列腺血液液体活检方法的最新进展。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000672
Andi K Cani, Simpa S Salami
{"title":"Recent Advances in Blood-Based Liquid Biopsy Approaches in Prostate Cancer.","authors":"Andi K Cani, Simpa S Salami","doi":"10.1097/PPO.0000000000000672","DOIUrl":"10.1097/PPO.0000000000000672","url":null,"abstract":"<p><strong>Abstract: </strong>The advent of high-throughput technologies has enabled the analysis of minute amounts of tumor-derived material purified from body fluids, termed \"liquid biopsies.\" Prostate cancer (PCa) management, like in many other cancer types, has benefited from liquid biopsies at several stages of the disease. Although initially describing circulating tumor cells in blood, the term \"liquid biopsy\" has come to more prominently include cell-free, circulating tumor DNA, as well as RNA, proteins, and other molecules. They provide tumor molecular information representing the entire, often-heterogeneous disease, relatively noninvasively and longitudinally. Blood has been the main liquid biopsy specimen in PCa, and urine has also proven beneficial. Technological advances have allowed clinical implementation of some liquid biopsies in PCa, in disease monitoring and precision oncology. This narrative review introduces the main types of blood-based PCa liquid biopsies focusing on advances in the past 5 years. Clinical adoption of liquid biopsies to detect and monitor the evolving PCa tumor biology promises to deepen our understanding of the disease and improve patient outcomes.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 4","pages":"220-225"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10262144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Utility of Interim Positron Emission Tomography Imaging to Inform Adaptive Radiotherapy for Head and Neck Squamous Cell Carcinoma. 中期正电子发射断层成像在头颈部鳞状细胞癌适应性放射治疗中的应用。
IF 2.2 4区 医学
Cancer journal Pub Date : 2023-07-01 DOI: 10.1097/PPO.0000000000000669
Benjamin S Rosen, Neil Vaishampayan, Yue Cao, Michelle L Mierzwa
{"title":"The Utility of Interim Positron Emission Tomography Imaging to Inform Adaptive Radiotherapy for Head and Neck Squamous Cell Carcinoma.","authors":"Benjamin S Rosen,&nbsp;Neil Vaishampayan,&nbsp;Yue Cao,&nbsp;Michelle L Mierzwa","doi":"10.1097/PPO.0000000000000669","DOIUrl":"10.1097/PPO.0000000000000669","url":null,"abstract":"<p><strong>Abstract: </strong>In this article, as part of this special issue on biomarkers of early response, we review the current evidence to support the use of positron emission tomography (PET) imaging during chemoradiation therapy to inform biologically adaptive radiotherapy for head and neck squamous cell carcinoma. We review literature covering this topic spanning nearly 3 decades, including the use of various radiotracers and discoveries of novel predictive PET biomarkers. Through understanding how observational trials have informed current interventional clinical trials, we hope that this review will encourage researchers and clinicians to incorporate PET response criteria in new trial designs to advance biologically optimized radiotherapy.</p>","PeriodicalId":9655,"journal":{"name":"Cancer journal","volume":"29 4","pages":"243-247"},"PeriodicalIF":2.2,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9845070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信